Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring homologous recombination repair deficiency (HRD) who have received prior therapy.

NCT Number	NCT07005583
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Triple-Negative Breast Cancer (TNBC)
Enrollment	46 participants
Start Date	2025-06-30
Primary Completion	2027-05-30 (estimated)
Study Completion	2030-05-20 (estimated)
Updated on ClinicalTrials.gov	2025-06-05